In prior research (37, 38), blockade of FGF23 signaling using anti-FGF23 antibody administration for 28 days in 6-day-old Dmp1KO mice fully corrected hypophosphatemia, bone growth, and trabecular bone volume and partially corrected cortical bone mineralization. The gene discussed is FGF23; the disease is hypophosphatemia.